S. Chmael

发表

A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion.

V. Devita, B. Burtness, J. Marsh, 2000, Cancer journal.

Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.

L. Pusztai, G. Israel, L. Harris, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.